Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[(Isopropylamino)Methyl]Phenylalanine is a synthetic derivative of the amino acid phenylalanine, featuring an isopropylamino group attached to the para position of the phenyl ring. This modification distinguishes it from natural phenylalanine and other derivatives. The compound has a molecular formula of C13H20N2O2 and a molecular weight of approximately 236.31 g/mol[1][5]. It is classified as a small molecule and has been primarily studied in experimental settings rather than clinical use[3]. Research suggests that this compound may modulate neurotransmitter pathways due to its structural similarity to phenylalanine, which is involved in dopamine and norepinephrine synthesis. Its unique substitution pattern could enhance biological activity or therapeutic potential for neurological disorders, but there are no approved indications or advanced clinical trials reported for this molecule[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[(Isopropylamino)Methyl]Phenylalanine.